sur AMOEBA (EPA:ALMIB)
Amoéba's 2025 Results: Regulatory Progress and Commercialisation Plan for 2026
Amoéba, a greentech firm from Chassieu, France, reported its 2025 audited results, highlighting significant regulatory advancements. The French ANSES is reviewing the AXPERA biocontrol product for marketing approval. Collaborations with Koppert and Syngenta, key players in biocontrol, strengthened Amoéba's commercial foothold.
Revenue remained absent, but financial investments reflected growth efforts. Industrial deployment costs rose by €1,082k, while marketing expenses increased by €216k, indicating preparation for the 2026 commercial launch. However, research and administrative costs declined, showcasing efficient cost management.
The company saw a net loss of €8,303k for 2025 but secured financial backing, improving its cash position to €4,722k. Amoéba expects sustained operations with support from Nice & Green until late 2026.
Looking forward, Amoéba anticipates the 2026 transition to commercial operations, leveraging partnerships and regulatory approvals to establish a notable market presence in biocontrol and cosmetics.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de AMOEBA